GlassScriptPhysician profile
Gillian Paige Reed
NPI 1568198778
$1,414.24
in general payments reported to CMS, 2019-2025
31 companies · $399 in 2025
The $399 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $254 · 2023: $427 · 2024: $334 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,160.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $180.02 | 2023-2024 | Opdivo |
| Beigene USA, INC. | $138.29 | 2024 | Brukinsa |
| Teleflex LLC | $136.67 | 2023 | Urolift |
| Seagen INC. | $96.51 | 2022 | |
| Pfizer INC. | $71.76 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $58.53 | 2022-2023 | |
| Janssen Biotech, INC. | $52.68 | 2023-2025 | Darzalex, Tecvayli, Talvey |
| Sobi, INC | $52.16 | 2024-2025 | |
| Incyte Corporation | $50.09 | 2025 | Monjuvi, Zynyz, Jakafi |
| Morphosys, US INC. | $47.18 | 2022-2023 | Monjuvi |
| Takeda Pharmaceuticals U.S.A., INC. | $38.69 | 2023-2025 | Ninlaro |
| Genentech USA, INC. | $37.83 | 2022-2025 | Polivy |
| Kyowa Kirin, INC. | $35.92 | 2022-2025 | |
| Celgene Corporation | $34.48 | 2023-2025 | Reblozyl, Pomalyst |
| Ipsen Biopharmaceuticals, INC | $34.30 | 2022-2023 | Somatuline Depot, Onivyde |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Legend Biotech USA INC. | $33.52 | 2025 | Carvykti |
| Karyopharm Therapeutics INC. | $31.83 | 2025 | Xpovio |
| Mirati Therapeutics, INC. | $31.47 | 2023 | Krazati |
| Astellas Pharma US INC | $27.50 | 2025 | Vyloy |
| Genzyme Corporation | $27.35 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.48 | 2023 | Gilotrif |
| Puma Biotechnology, INC. | $22.87 | 2023 | |
| Novartis Pharmaceuticals Corporation | $22.10 | 2025 | |
| Kite Pharma, INC. | $19.88 | 2025 | Yescarta |
| Daiichi Sankyo INC. | $18.72 | 2022 | |
| Servier Pharmaceuticals LLC | $18.12 | 2025 | |
| Abbvie INC. | $15.46 | 2025 | |
| Alexion Pharmaceuticals, INC. | $13.96 | 2023 | Ultomiris |
| Syndax Pharmaceuticals, INC. | $13.90 | 2025 | |
| Eisai INC. | $13.27 | 2024 | |
| Kerecis Limited | $12.70 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gillian Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.